Analyst Research
| Report Title | Price |
|---|---|
|
Provider: Pechala's Reports
|
$15.00
|
|
Provider: Reuters Investment Profile
|
$20.00
|
|
Provider: Thomson Reuters Stock Report
|
$25.00
|
|
Provider: Jefferson Research
|
$20.00
|
NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.
Glaxosmithkline Plc Set For Human Genome Sciences Inc Takeover-Reuters
Reuters reported that Glaxosmithkline Plc is expected to announce an agreement to acquire Human Genome Sciences Inc for about $2.8 billion as soon as Monday, ending three months of its hostile pursuit of the U.S. biotechnology company. Glaxosmithkline is expected to pay around $14 per share, sweetening the offer from its previous $13 per share bid. A deal is expected to be announced before the U.S. stock market opens, they said, asking not to be identified because the matter is not public. The deal has yet to be finalized and the companies are still working out last-minute details.
Latest Developments for GlaxoSmithKline PLC
- Elan Corporation PLC Strikes $1 Billion GlaxoSmithKline Plc Royalty Deal With Theravance Inc-Reuters
- FDA Approves Glaxosmithkline Plc's Breo Ellipta To Treat Lung Disease Jointly Developed With Theravance Inc-DJ
- Glaxosmithkline Plc Opts To Sell Off Lucozade And Ribena Drink Brands-Reuters
- Glaxosmithkline Plc Reaffirms FY 2013 Guidance; Declares First Interim Dividend
Latest Key Developments in Pharmaceuticals
- AmerisourceBergen Corp Reaffirms FY 2013 EPS Gudiance-Conference Call
- Immunotec Inc Announces New CEO
- Novo Nordisk A/S Reports Positive Results from First Phase 3 Trial with Long-Acting Factor IX for Treatment of Haemophilia B
- Sanofi SA Announces Positive Results on Pivotal Study of Inhibitor in Myelofibrosis-DJ
- Share this
- Link this
- Digg this
Follow Reuters